Search

Purpose To characterize patterns of use, efficacy, and safety of dexamethasone intravitreal implant (DEX) in treatment of macular edema (ME) due to retinal vein occlusion (RVO) in the French clinical setting. Methods A 24-month, observational, prospective, epidemiological study conducted at 48 randomly selected sites in France enrolled consecutive patients with ME due to RVO who were treated with DEX at baseline. DEX re-treatment and use of other RVO treatments was at the physician's discretion. The primary endpoint was change in best-corrected visual acuity (BCVA) from baseline to month 6. Secondary endpoints included BCVA change from baseline and adverse events through month 24. Results Patients (n = 375) received a mean of 2.6 DEX injections (range, 1-7) over 2 years; 167 received DEX only and 208 also received other types of RVO treatment. Mean (SD) change from baseline BCVA was +5.1 (19.0) ETDRS letters at month 6 (P < 0.001) and +4.6 (22.3) letters at month 24 (P < 0.001). For patients treated only with DEX during the study, mean (SD) change from baseline BCVA was +8.1 (20.9) letters (P < 0.001) at 24 months, compared with +2.5 (23.0) letters (P = 0.092) for patients moved to other treatments. BCVA improved significantly from baseline at 6 and 24 months in subgroups defined by diagnosis (branch RVO, central RVO), previous treatment, duration of ME, and pattern of DEX use. The most common adverse events were ocular hypertension and cataract. Conclusions Patients with RVO-related ME treated with DEX in the French clinical setting had efficacy and safety outcomes similar to those seen in the phase 3 registration trials. BCVA gains were maintained over 2 years and largest in patients with recent onset (<3 months) ME, confirming the benefit of early treatment. [ABSTRACT FROM AUTHOR]

Purpose To describe the course of functional and anatomical damage after successful repair of macula-off rhegmatogenous retinal detachment ( RRD). Methods This was a prospective multicenter study including patients with successful surgery for macula-off RRD between October 2011 and April 2014. Patients with pre-existing macular diseases or with surgery failures were excluded. Each patient underwent a complete ophthalmologic exam at baseline and at one, three and six months after the surgery (M1, M3, M6), with an assessment of the best-corrected visual acuity ( BCVA) at 4 m using the standard Early Treatment Diabetic Retinopathy Study chart, and with Spectral-Domain Optical Coherence Tomography ( SD- OCT) macular imaging. Results One hundred and three eyes of 103 patients from ten French centers, with a 63-years median age ( IQR: [58; 69]), were included. The median BCVA increased significantly from 63 [46; 73] letters at M1 to 73 [62; 80]) at M6, p < 0.01). SD- OCT morphologic lesions in the outer retina significantly improved between M1 and M6: irregular hyporeflectivity of the photoreceptor outer segments (76.7% vs 61.5%, p < 0.01) and disruption of the inner/outer segment junction line (51.5% vs 26.2%, p < 0.01). The rate of epiretinal membrane did not significantly increase between M1 and M6 (9.7% vs 20.4%, p < 0.67). Conclusions These preliminary results of the study 'DécOllement de REtine: Fonction et Anatomie ( DOREFA)' show a slow recovery of the external retinal layers after a successful RRD surgery. These observations seem to be parallel to the progressive recovery of the visual function after the intervention. A better knowledge of functional and anatomical kinetics after macula-off RRD constitutes a preliminary step to the study of factors influencing the visual prognosis. [ABSTRACT FROM AUTHOR]